文献速递冠心病血脂与心血管预防

血液透析患者中甘油三酯沉积性心肌血管病的患病率与临床结局

Prevalence and clinical outcomes of triglyceride deposit cardiomyovasculopathy among haemodialysis patients.
PubMed 文献 · Heart · 2020-09-30

该回顾性单中心观察研究纳入2011年4月至2017年3月日本成田纪念医院654例连续血液透析患者,其中83例疑似冠心病者接受碘-123标记的β-甲基碘苯基十五烷酸闪烁显像和冠状动脉造影。患者分为确诊TGCV组17例、疑似TGCV组22例和非TGCV对照组44例。中位随访4.7年,确诊TGCV组主要终点发生率为52.9%,显著高于对照组的9.1%(HR 7.45,95%CI 2.28-24.3,p<0.001)。

要点

  • 在疑似冠心病的血液透析患者中,确诊TGCV患病率约20%,在所有血液透析患者中约2.6%。
  • 确诊TGCV与血液透析患者心血管死亡和心血管事件风险显著独立相关。
  • TGCV可能成为血液透析患者心血管事件预防的潜在治疗靶点。

核心结论

  • TGCV在血液透析患者中并不少见,且与包括心血管死亡在内的心血管事件风险增加相关。

研究设计与样本

  • 回顾性单中心观察研究,纳入2011年4月至2017年3月成田纪念医院心导管数据库654例连续血液透析患者,其中83例疑似冠心病者接受碘-123标记的β-甲基碘苯基十五烷酸闪烁显像和冠状动脉造影。

主要发现

  • 确诊TGCV在疑似冠心病的连续血液透析患者中患病率约20%,在所有血液透析患者中约2.6%。
  • 中位随访4.7年,确诊TGCV组主要终点发生率为52.9%(HR 7.45,95%CI 2.28-24.3,p<0.001),疑似TGCV组为27.3%(HR 3.28,95%CI 0.93-11.6,p=0.066),非TGCV对照组为9.1%。
  • 在所有多变量模型中,确诊TGCV与血液透析患者心血管死亡和结局显著独立相关。

临床怎么用

  • 对血液透析合并疑似冠心病的患者,可考虑评估TGCV以识别心血管事件高危人群。

局限性

  • 回顾性单中心观察研究,样本量有限,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of triglyceride deposit cardiomyovasculopathy (TGCV) on the cardiovascular outcomes in haemodialysis (HD) patients with suspected coronary artery disease (CAD). METHODS: This retrospective single-centre observational study included data from the cardiac catheter database of Narita Memorial Hospital between April 2011 and March 2017. Among 654 consecutive patients on HD, the data for 83 patients with suspected CAD who underwent both [123I]-β-methyl-iodophenyl-pentadecanoic acid scintigraphy and coronary angiography were analysed. Patients were divided into three groups: definite TGCV (17 patients), probable TGCV (22 patients) and non-TGCV control group (44 patients). The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke assessed for up to 5 years of follow-up. RESULTS: The prevalence of definite TGCV was approximately 20% and 2.6% among consecutive HD patients with suspected CAD and among all HD patients, respectively. At the end of the median follow-up period of 4.7 years, the primary endpoint was achieved in 52.9% of the definite TGCV patients (HR, 7.45; 95% CI: 2.28 to 24.3; p<0.001) and 27.3% of the probable TGCV patients (HR, 3.28; 95% CI: 0.93 to 11.6; p=0.066), compared with that in 9.1% of the non-TGCV control patients. Definite TGCV was significantly and independently associated with cardiovascular mortality and outcomes among HD patients in all multivariate models. CONCLUSIONS: TGCV is not uncommon in HD patients and is associated with an increased risk of cardiovascular events including cardiovascular death. Thus, TGCV might be a potential therapeutic target.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Onishi T, Nakano Y, Hirano KI, et al. Prevalence and clinical outcomes of triglyceride deposit cardiomyovasculopathy among haemodialysis patients. Heart. 2020. PMID: 32998957. doi:10.1136/heartjnl-2020-317672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。